Evidence mapPaperPMID 41277871Full record

ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026

Triage and care for women with symptoms or diagnosis of pregnancy loss between 14 + 0 and 21 + 6 weeks' gestation.

Caroline E Fox, Rosinder Kaur, Kugajeevan Vigneswaran, Rachel Small, Jenny Carter, Keelin O'Donoghue, Alexander E P Heazell, Anna L David, Nigel Simpson, Angharad Care and 8 more

Abstract read
In one paragraph

Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Triage and care for women with symptoms or diagnosis of pregnancy loss between 14 + 0 and 21 + 6 weeks' gestation.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Caroline E FoxBirmingham Women's and Hospital, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.ORCID https://orcid.org/0000-0002-0150-8282
Rosinder KaurTommy's National Centre for Miscarriage Research, Birmingham, UK.
Kugajeevan VigneswaranTommy's National Centre for Miscarriage Research, Birmingham, UK.
Rachel SmallBirmingham Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Jenny CarterDepartment of Women and Children's Health, King's College London, London, UK.
Keelin O'DonoghuePregnancy Loss Research Group, University College Cork, Cork, Ireland.
Alexander E P HeazellUniversity of Manchester, Manchester, UK.
Anna L DavidTommy's National Centre for Preterm Birth Research, London, UK.
Nigel SimpsonDepartment of Women and Children's Health, King's College London, London, UK.
Angharad CareLiverpool Women's Hospital, Liverpool Women's NHS Foundation Trust, Liverpool, UK.
Lisa StarrsRoyal Infirmary of Edinburgh, NHS Lothian, Edinburgh, Scotland, UK.
Andrew ShennanDepartment of Women and Children's Health, King's College London, London, UK.
Catalina María Valencia GonzálezUniversidad Colegio Mayor de Nuestra Señora del Rosario, Bogota, Colombia.
Priya Soma-PillayUniversity of Pretoria, Pretoria, South Africa.
Leah FitzsimmonsTommy's National Centre for Miscarriage Research, Birmingham, UK.
Adam J DevallTommy's National Centre for Miscarriage Research, Birmingham, UK.
Arri CoomarasamyTommy's National Centre for Miscarriage Research, Birmingham, UK.
Mid‐trimester Pregnancy Loss Guideline Consensus Panel

Funding

Tommy's National Centre for Miscarriage Research
6 · The paper itself

Abstract

Mid-trimester pregnancy loss (MTL), defined as a pregnancy loss occurring between 14 + 0 and 21 + 6 weeks of gestation, causes significant physical and emotional distress to women and presents clinical challenges to healthcare professionals. It is acknowledged that in low-resource settings, this guideline might be applicable to births up to 28 weeks or babies weighing less than 1 kg. Risk factors for MTL include advanced maternal age, previous history of MTL, women of Black ethnicity, smoking, excessive alcohol consumption, obesity, and anatomical factors such as a short cervix, congenital uterine anomalies, and myomas. Medical risk factors include previous cervical trauma from loop electrosurgical excision procedure or Cesarean section in labor, placental dysfunction, infections, thrombophilias, endocrine disorders such as thyroid disease and polycystic ovary syndrome, and fetal chromosomal abnormalities. Early assessment and accurate diagnosis are fundamental to managing threatened and confirmed mid-trimester pregnancy loss. Our guideline emphasizes the importance of maternal vital signs monitoring, laboratory investigations, and ultrasound imaging to identify and manage those with threatened or confirmed mid-trimester pregnancy loss, as well as address potential maternal complications, including infection or hemorrhage. A multidisciplinary approach involving obstetricians, gynecologists, maternal-fetal medicine specialists, nurses, midwives, psychologists, and social workers is important for providing comprehensive care. The guideline advocates for personalized management plans tailored to individual women's preferences, medical history, and gestational age. Care for threatened MTL should be targeted to the likely cause and might include cervical cerclage, progesterone, and management of risk factors, for example antibiotics for urinary tract infections. Care for confirmed MTL might include expectant management, medical induction of labor, or surgical intervention such as dilation and evacuation. Acknowledging the profound emotional impact of mid-trimester pregnancy loss, our guideline underscores the importance of offering compassionate and culturally sensitive psychosocial support to women and their families. This includes providing access to bereavement care, counseling services, support groups, and resources for coping with grief and loss. Continued monitoring and follow-up care are essential components of managing mid-trimester pregnancy loss. Our guideline recommends regular postpartum assessments to evaluate physical recovery and emotional well-being and to address any ongoing medical or psychological concerns. Contraceptive counseling and future pregnancy planning should also be discussed as part of comprehensive care. It is important that, where possible, women receive continuity of care from healthcare professionals to help the coordination and provision of holistic and comprehensive care. Further research is needed to enhance our understanding of the etiology, risk factors, and optimal management strategies for threatened mid-trimester pregnancy loss. Additionally, education and training initiatives should be implemented to ensure healthcare professionals are equipped with the knowledge and skills necessary to deliver high-quality, woman-centered care to individuals and families experiencing this complication. Mid-trimester pregnancy loss represents a complex clinical scenario necessitating a holistic and compassionate approach to care. By adhering to the recommendations outlined in this clinical guideline, healthcare providers can strive to optimize outcomes and support individuals and their families through this challenging experience.

Indexed as

Abortion, SpontaneousTriageFemaleGestational AgeHumansPregnancyPregnancy Trimester, SecondPrenatal CareRisk Factorsdiagnosis and managementmiscarriagepregnancy losssecond‐trimester losstriage

Identifiers

PMID41277871
PMCPMC12724057

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.